Recent developments in the immunology of inflammatory bowel disease
- PMID: 10632969
- DOI: 10.1046/j.1365-3083.2000.00658.x
Recent developments in the immunology of inflammatory bowel disease
Abstract
Crohn's disease and ulcerative colitis are caused by excessive immune reactivity in the gut wall. Analysis of the type of immune responses ongoing in diseased gut has revealed important features which suggest that these conditions are different. In Crohn's disease tissue there is considerable evidence for an ongoing T helper cell type 1 response, with excess interleukin-12, interferon-gamma and TNF-alpha. There is circumstantial evidence in patients that this response is directed against the normal bacterial flora and definitive evidence in mouse models that T cell responses to the flora cause gut disease. In ulcerative colitis, the role of tissue damaging T cell responses in the gut mucosa is much less clear and there is more evidence that the lesion is owing to antibody-mediated hypersensitivity. Although different types of immune reactions initiate tissue injury in both Crohn's disease and ulcerative colitis, the downstream events which actually damage the tissue are the same in each condition. Elevated cytokine concentrations in the mucosa lead to the production of excess matrix degrading enzymes by gut fibroblasts, loss of mucosal integrity and ulceration. The same process also leads to an increased production of epithelial growth factors such as KGF Keratinocyte Growth Factor by gut fibroblasts and produces the crypt cell hyperplasia characteristic of all gut inflammatory conditions.
Similar articles
-
Manipulation of cytokines in the management of patients with inflammatory bowel disease.Ann Med. 2000 Nov;32(8):552-60. doi: 10.3109/07853890008998835. Ann Med. 2000. PMID: 11127933 Review.
-
Immune system alterations in patients with inflammatory bowel disease during remission.Medicina (Kaunas). 2008;44(1):27-33. Medicina (Kaunas). 2008. PMID: 18277086
-
Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease.Gastroenterology. 1991 Dec;101(6):1594-605. doi: 10.1016/0016-5085(91)90397-4. Gastroenterology. 1991. PMID: 1683326
-
[Immunopathogenesis of inflammatory bowel diseases].Chirurg. 2000 Jan;71(1):30-40. doi: 10.1007/s001040050005. Chirurg. 2000. PMID: 10662999 Review. German.
-
Immunoregulation in the gut: success and failures in human disease.Gut. 2002 May;50 Suppl 3(Suppl 3):III60-4. doi: 10.1136/gut.50.suppl_3.iii60. Gut. 2002. PMID: 11953335 Free PMC article. Review.
Cited by
-
Schistosoma japonicum ova maintains epithelial barrier function during experimental colitis.World J Gastroenterol. 2011 Nov 21;17(43):4810-6. doi: 10.3748/wjg.v17.i43.4810. World J Gastroenterol. 2011. PMID: 22147983 Free PMC article.
-
Downregulation of electroacupuncture at ST36 on TNF-alpha in rats with ulcerative colitis.World J Gastroenterol. 2003 May;9(5):1028-33. doi: 10.3748/wjg.v9.i5.1028. World J Gastroenterol. 2003. PMID: 12717850 Free PMC article.
-
Analysis of gene expression in ceca of Helicobacter hepaticus-infected A/JCr mice before and after development of typhlitis.Infect Immun. 2003 Jul;71(7):3885-93. doi: 10.1128/IAI.71.7.3885-3893.2003. Infect Immun. 2003. PMID: 12819073 Free PMC article.
-
Clinical aspects and pathophysiology of inflammatory bowel disease.Clin Microbiol Rev. 2002 Jan;15(1):79-94. doi: 10.1128/CMR.15.1.79-94.2002. Clin Microbiol Rev. 2002. PMID: 11781268 Free PMC article. Review.
-
TNF ligands and receptors--a matter of life and death.Br J Pharmacol. 2002 Feb;135(4):855-75. doi: 10.1038/sj.bjp.0704549. Br J Pharmacol. 2002. PMID: 11861313 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources